Human Recombinant KMT2D, Active protein, GST Tag (V2LY-0526-LY5201)

Name: Human Recombinant KMT2D, Active protein, GST Tag
SKU: V2LY-0526-LY5201
Rating: 5 (1 reviews)

See all KMT2D antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host

Baculovirus-Insect Cells

Protein Species

Human

Tag

GST Tag

Protein Construction

This product is Human Recombinant KMT2D, Active protein, GST Tag consist of Amino Acid: 5317-end and predicts a molecular mass of 51 kDa.

Molecule Mass

51 kDa

Sequence

Amino Acid: 5317-end

Species

Human

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity

Batch dependent.

Endotoxin

Please contact us for more information.

Format

Liquid

Buffer

Tris, NaCl, Glutathione, EDTA, DTT, PMSF, Glycerol

Preservative

None

Storage

Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

More Infomation

Target

Full Name

LYSINE METHYLTRANSFERASE 2D

Function

Histone methyltransferase that catalyzes methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) (PubMed:25561738).
Part of chromatin remodeling machinery predominantly forms H3K4me1 methylation marks at active chromatin sites where transcription and DNA repair take place (PubMed:25561738, PubMed:17500065).
Acts as a coactivator for estrogen receptor by being recruited by ESR1, thereby activating transcription (PubMed:16603732).

Cellular Location

Nucleus

Involvement in disease

Kabuki syndrome 1 (KABUK1):
A congenital mental retardation syndrome with additional features, including postnatal dwarfism, a peculiar facies characterized by long palpebral fissures with eversion of the lateral third of the lower eyelids, a broad and depressed nasal tip, large prominent earlobes, a cleft or high-arched palate, scoliosis, short fifth finger, persistence of fingerpads, radiographic abnormalities of the vertebrae, hands, and hip joints, and recurrent otitis media in infancy.

Dhar, S. S., & Lee, M. G. (2021). Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors. Oncotarget, 12(13), 1296.

Heward, J., Koniali, L., D’Avola, A., Close, K., Yeomans, A., Philpott, M., ... & Fitzgibbon, J. (2021). KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood, The Journal of the American Society of Hematology, 138(5), 370-381.

Alam, H., Tang, M., Maitituoheti, M., Dhar, S. S., Kumar, M., Han, C. Y., ... & Lee, M. G. (2020). KMT2D deficiency impairs super-enhancers to confer a glycolytic vulnerability in lung cancer. Cancer cell, 37(4), 599-617.

Wang, G., Chow, R. D., Zhu, L., Bai, Z., Ye, L., Zhang, F., ... & Chen, S. (2020). CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade. Cancer discovery, 10(12), 1912-1933.

Sun, P., Wu, T., Sun, X., Cui, Z., Zhang, H., Xia, Q., & Zhang, D. (2019). KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes. Biomedicine & Pharmacotherapy, 115, 108924.

Fagan, R. J., & Dingwall, A. K. (2019). COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer. Cancer letters, 458, 56-65.

Li, S. S., Jiang, W. L., Xiao, W. Q., Li, K., Zhang, Y. F., Guo, X. Y., ... & Wan, R. (2019). KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma. World Journal of Gastrointestinal Oncology, 11(8), 599.

Xiong, W., Deng, Z., Tang, Y., Deng, Z., & Li, M. (2018). Downregulation of KMT2D suppresses proliferation and induces apoptosis of gastric cancer. Biochemical and biophysical research communications, 504(1), 129-136.

Ardeshir-Larijani, F., Bhateja, P., Lipka, M. B., Sharma, N., Fu, P., & Dowlati, A. (2018). KMT2D mutation is associated with poor prognosis in non–small-cell lung cancer. Clinical lung cancer, 19(4), e489-e501.

Lv, S., Ji, L., Chen, B., Liu, S., Lei, C., Liu, X., ... & Lu, L. (2018). Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4. Oncogene, 37(10), 1354-1368.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Human Recombinant KMT2D, Active protein, GST Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-KMT2D Recombinant Antibody (CBT3062) (CAT#: V2LY-0625-LY1315)

Mouse Anti-KMT2D Recombinant Antibody (2E1) (CAT#: CBMAB-K1432-LY)

Mouse Anti-KMT2D Recombinant Antibody (2E1) (CAT#: CBMAB-A5512-LY)

Rabbit Anti-KMT2D Recombinant Antibody (9H13L17) (CAT#: CBMAB-K1433-LY)

Mouse Anti-KMT2D Recombinant Antibody (20) (CAT#: CBMAB-K1431-LY)

Mouse Anti-KMT2D Recombinant Antibody (CBT2412) (CAT#: V2LY-0625-LY1316)

Mouse Anti-KMT2D (AA 813-905) Recombinant Antibody (CBFYM-1194) (CAT#: CBMAB-M1351-FY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry